A5008372439- Ovarian cancer diagnosis and treatment
- Cervical Cancer and HPV Research
- HER2/EGFR in Cancer Research
- Endometrial and Cervical Cancer Treatments
- Neonatal Respiratory Health Research
- Infant Development and Preterm Care
- Lymphoma Diagnosis and Treatment
- Uterine Myomas and Treatments
- Cardiac Arrest and Resuscitation
- Gestational Trophoblastic Disease Studies
- Heart Rate Variability and Autonomic Control
- HIV Research and Treatment
- Preterm Birth and Chorioamnionitis
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Virology and Viral Diseases
- Sarcoma Diagnosis and Treatment
- Gynecological conditions and treatments
- Teratomas and Epidermoid Cysts
- Syphilis Diagnosis and Treatment
- Infant Nutrition and Health
- Reproductive tract infections research
- Cancer Immunotherapy and Biomarkers
- Antibiotic Resistance in Bacteria
- Renal cell carcinoma treatment
Yale University
2023-2025
Northwell Health
2024
Smilow Cancer Hospital
2024
Long Island Jewish Medical Center
2022-2024
East Tennessee State University
2023
North Shore University Hospital
2021-2022
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2021
Center for Global Health
2016
Johns Hopkins University
2016
Centers for Disease Control and Prevention
2016
Despite the growing importance of carbapenem-resistant Klebsiella pneumoniae (CRKP), clonal relationships between CRKP and antibiotic-susceptible isolates remain unclear. We compared genetic diversity clinical features CRKP, third-generation and/or fourth-generation cephalosporin-resistant (Ceph-R) K. pneumoniae, susceptible causing bloodstream infections at a tertiary care hospital in New York City January 2012 July 2013. Drug susceptibilities were determined with Vitek 2 system. Isolates...
High-grade neuroendocrine cervical cancers (NETc) are exceedingly rare, highly aggressive tumors. We analyzed 64 NETc tumor samples by whole-exome sequencing (WES). Human papillomavirus DNA was detected in 65.6% (42/64) of the Recurrent mutations were identified PIK3CA, KMT2D/MLL2, K-RAS, ARID1A, NOTCH2, and RPL10. The top mutated genes included RB1, PTEN, KMT2D / MLL2, WDFY3, a gene not yet implicated NETc. Somatic CNV analysis two copy number gains (3q27.1 19q13.12) five losses...
Abstract Purpose: We report the results of a randomized phase II trial imiquimod, topical immune-response modulator versus imiquimod plus 9-valent human papillomavirus (HPV) vaccine (9vHPV) clinical surveillance in cervical intraepithelial neoplasia (CIN2/3) patients. Patients and Methods: randomly allocated 133 patients with untreated CIN2/3 equal proportions to 4-month treatment self-applied vaginal suppositories containing (Arm B) or 9vHPV C) A). The main outcome was efficacy, defined as...
High-grade endometrial cancers (EAC) are aggressive tumors with a high risk of progression after treatment. As EAC may harbor mutations in the RAS/MAPK pathways, we evaluated preclinical vitro and vivo efficacy avutometinib, RAF/MEK clamp, combination focal adhesion kinase (FAK) inhibitors defactinib or VS-4718, against multiple primary cell lines xenografts.
Abstract Objective: Uterine serous carcinoma is a rare biologically aggressive type of endometrial cancer associated with high rate mortality. Datopotamab deruxtecan (Dato-DXd) novel ADC composed the humanized anti-TROP2 IgG1 monoclonal antibody, cleavable tetrapeptide linker, and topoisomerase I inhibitor payload. TROP2 expression detected in up to 95% uterine (USC) cases, making it an excellent target for therapy. We evaluated preclinical activity Dato-DXd vitro against primary USC cell...
Abstract Uterine serous carcinoma (USC) is a rare subset of endometrial cancer with poor prognosis and high recurrence rate. Datopotamab-deruxtecan (Dato-DXd) novel antibody-drug-conjugate (ADC). The objective this study was to evaluate the preclinical activity Dato-DXd in USC vitro against primary cell lines various TROP2 expression vivo overexpressing cell-line derived mice xenografts. tumor were treated control ADC (CTL ADC) viability following exposure....
<p>DNA breakage induced from cell internalization of DXd represented by the phosphorylation H2AX. Greater staining at doses 5 μg/mL seen with Dato-DXd treatment compared CTL ADC.</p>
<p>ADCC results of Dato-DXd, datopotamab, rituximab, and CTL ADC in representative (<b>A</b>) ARK2 USC TROP2 3+, (<b>B</b>) ARK20 (<b>C</b>) ARK1 TROP2-nonexpressing cell lines.</p>
<div>Abstract<p>Uterine serous carcinoma (USC) is a rare subset of endometrial cancer with poor prognosis and high recurrence rate. Datopotamab deruxtecan (Dato-DXd) novel antibody–drug conjugate (ADC). The objective this study was to evaluate the preclinical activity Dato-DXd in USC <i>in vitro</i> against primary cell lines various trophoblast cell-surface antigen 2 (TROP2) expression vivo</i> TROP2-overexpressing line–derived mice xenografts. tumor were...
<p>IC<sub>50</sub> value dose–response curves of Dato-DXd and CTL ADC in USC cell lines with variable TROP2 expression. <b>A,</b> 3+ ARK2 line: the mean IC<sub>50</sub> was 0.11 μg/mL vs. 30.07 for (<i>P</i> = 0.0074). <b>B,</b> ARK20 48.95 0.0127). <b>C,</b> 1+ ARK7 80.38 61.79 ADC. <b>D,</b> ARK1 18.49 17.12 0.65).</p>
<p>Characteristics and demographics of USC cell lines</p>
<p>Bystander antitumor effect of TROP2-nonexpressing USC cells (ARK-4) when cocultured with TROP2 3+ ARK2 cell line treated 0.5 μg/mL Dato-DXd vs. CTL ADC. had little on ARK-4 they were cultured alone (83% lives cells); however, was ARK2, induced significantly more killing (64.8% live cells, <i>P</i> = 0.0231). ADC did not have significant coculture (95% cells).</p>
<p>Antitumor activity in mice inoculated with TROP2 3+ USC ARK2 xenograft tumor models (CDXs). <b>A,</b> CDX volumes after treatment Dato-DXd, datopotamab, CTL ADC, and vehicle control (PBS). Dato-DXd demonstrates significant growth inhibition compared CTL. <b>B,</b> OS a single retro-orbital vehicle. was significantly prolonged among Dato-DXd–treated groups other groups.</p>
Measles and congenital rubella syndrome remain significant causes of morbidity mortality despite available vaccines. HIV-infected youth may be at increased risk measles because greater waning immunity after vaccination. At a population level, they constitute potentially large pool susceptibles to rubella. More data among in sub-Saharan Africa are needed guide vaccination policy control strategies.